TW202112379A - 治療及／或預防乾癬之方法 - Google Patents
治療及／或預防乾癬之方法 Download PDFInfo
- Publication number
- TW202112379A TW202112379A TW109118991A TW109118991A TW202112379A TW 202112379 A TW202112379 A TW 202112379A TW 109118991 A TW109118991 A TW 109118991A TW 109118991 A TW109118991 A TW 109118991A TW 202112379 A TW202112379 A TW 202112379A
- Authority
- TW
- Taiwan
- Prior art keywords
- days
- administered
- subject
- day
- affected area
- Prior art date
Links
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 105
- 238000000034 method Methods 0.000 title abstract description 242
- HUNGUWOZPQBXGX-UHFFFAOYSA-N tirbanibulin Chemical compound C=1C=CC=CC=1CNC(=O)CC(N=C1)=CC=C1C(C=C1)=CC=C1OCCN1CCOCC1 HUNGUWOZPQBXGX-UHFFFAOYSA-N 0.000 claims abstract description 379
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 60
- 230000000694 effects Effects 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 206010040914 Skin reaction Diseases 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 230000035483 skin reaction Effects 0.000 claims description 8
- 231100000430 skin reaction Toxicity 0.000 claims description 8
- 230000002411 adverse Effects 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000003902 lesion Effects 0.000 description 24
- 229940079593 drug Drugs 0.000 description 12
- 239000002674 ointment Substances 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 10
- 230000000699 topical effect Effects 0.000 description 10
- 238000011160 research Methods 0.000 description 9
- 230000009885 systemic effect Effects 0.000 description 9
- 206010040844 Skin exfoliation Diseases 0.000 description 8
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 206010015150 Erythema Diseases 0.000 description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000001126 phototherapy Methods 0.000 description 6
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 230000035618 desquamation Effects 0.000 description 5
- 210000003127 knee Anatomy 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 210000004761 scalp Anatomy 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 206010003051 Application site pain Diseases 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 4
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 206010033733 Papule Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 229940028334 follicle stimulating hormone Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000009597 pregnancy test Methods 0.000 description 4
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 206010015278 Erythrodermic psoriasis Diseases 0.000 description 3
- 108010008165 Etanercept Proteins 0.000 description 3
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010037575 Pustular psoriasis Diseases 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 3
- 239000003433 contraceptive agent Substances 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 210000000744 eyelid Anatomy 0.000 description 3
- 210000000245 forearm Anatomy 0.000 description 3
- 210000001061 forehead Anatomy 0.000 description 3
- 229960000598 infliximab Drugs 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 206010049041 Application site infection Diseases 0.000 description 2
- 206010003046 Application site irritation Diseases 0.000 description 2
- 206010003053 Application site pruritus Diseases 0.000 description 2
- 206010053424 Application site swelling Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000003367 Hypopigmentation Diseases 0.000 description 2
- 208000035447 Orbital oedema Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002882 calcipotriol Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000004299 exfoliation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010018797 guttate psoriasis Diseases 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 208000000069 hyperpigmentation Diseases 0.000 description 2
- 230000003810 hyperpigmentation Effects 0.000 description 2
- 230000003425 hypopigmentation Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 244000309715 mini pig Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 231100000279 safety data Toxicity 0.000 description 2
- -1 salt compound Chemical class 0.000 description 2
- 229960004540 secukinumab Drugs 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000007332 vesicle formation Effects 0.000 description 2
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010051814 Eschar Diseases 0.000 description 1
- 206010015967 Eye swelling Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 244000179291 Mahonia aquifolium Species 0.000 description 1
- 235000002823 Mahonia aquifolium Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 229960002459 alefacept Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229960001164 apremilast Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000037896 autoimmune cutaneous disease Diseases 0.000 description 1
- 229940054720 avage Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 229960003735 brodalumab Drugs 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 229940010466 cosentyx Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940075049 dovonex Drugs 0.000 description 1
- 229940083260 dritho-scalp Drugs 0.000 description 1
- 229940075117 droxia Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 229940020485 elidel Drugs 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 210000004920 epithelial cell of skin Anatomy 0.000 description 1
- 231100000333 eschar Toxicity 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000020650 eye health related herbal supplements Nutrition 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940062737 gengraf Drugs 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 229950010864 guselkumab Drugs 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 229940096120 hydrea Drugs 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960005435 ixekizumab Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940063121 neoral Drugs 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 229940011530 otezla Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- KASDHRXLYQOAKZ-XDSKOBMDSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-XDSKOBMDSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940072288 prograf Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 150000004508 retinoic acid derivatives Chemical class 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940061969 rheumatrex Drugs 0.000 description 1
- 229950007943 risankizumab Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229940068638 simponi Drugs 0.000 description 1
- 208000010744 skin desquamation Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 229940071598 stelara Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 229940095374 tabloid Drugs 0.000 description 1
- 229940060681 taltz Drugs 0.000 description 1
- 229940036234 tazorac Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 229950005515 tildrakizumab Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 229940121511 tirbanibulin Drugs 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 229940040153 vectical Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962857796P | 2019-06-05 | 2019-06-05 | |
| US62/857,796 | 2019-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202112379A true TW202112379A (zh) | 2021-04-01 |
Family
ID=73653388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109118991A TW202112379A (zh) | 2019-06-05 | 2020-06-05 | 治療及／或預防乾癬之方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220305021A1 (https=) |
| EP (1) | EP3980021A4 (https=) |
| JP (2) | JP2022535267A (https=) |
| AU (1) | AU2020288640A1 (https=) |
| CA (1) | CA3142477A1 (https=) |
| IL (1) | IL288524A (https=) |
| TW (1) | TW202112379A (https=) |
| WO (1) | WO2020247706A1 (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7939529B2 (en) * | 2007-05-17 | 2011-05-10 | Kinex Pharmaceuticals, Llc | Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof |
| US7935697B2 (en) * | 2006-12-28 | 2011-05-03 | Kinex Pharmaceuticals, Llc | Compositions for modulating a kinase cascade and methods of use thereof |
| WO2015054500A2 (en) * | 2013-10-09 | 2015-04-16 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
| CA2969090C (en) * | 2014-12-23 | 2023-05-02 | Novartis Ag | Triazolopyrimidine compounds and uses thereof |
| RU2017134379A (ru) * | 2015-03-25 | 2019-04-03 | Новартис Аг | Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4 |
| CN118384166A (zh) * | 2016-08-12 | 2024-07-26 | 阿西纳斯公司 | 用于调节激酶级联的联芳组合物和方法 |
| WO2018165647A1 (en) * | 2017-03-10 | 2018-09-13 | Athenex, Inc. | Methods of treating and/or preventing actinic keratosis |
-
2020
- 2020-06-05 US US17/616,238 patent/US20220305021A1/en not_active Abandoned
- 2020-06-05 WO PCT/US2020/036238 patent/WO2020247706A1/en not_active Ceased
- 2020-06-05 AU AU2020288640A patent/AU2020288640A1/en not_active Abandoned
- 2020-06-05 CA CA3142477A patent/CA3142477A1/en active Pending
- 2020-06-05 JP JP2021571835A patent/JP2022535267A/ja active Pending
- 2020-06-05 EP EP20819597.4A patent/EP3980021A4/en not_active Withdrawn
- 2020-06-05 TW TW109118991A patent/TW202112379A/zh unknown
-
2021
- 2021-11-29 IL IL288524A patent/IL288524A/en unknown
-
2024
- 2024-11-15 JP JP2024199595A patent/JP2025032128A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022535267A (ja) | 2022-08-05 |
| EP3980021A1 (en) | 2022-04-13 |
| US20220305021A1 (en) | 2022-09-29 |
| AU2020288640A1 (en) | 2021-12-23 |
| IL288524A (en) | 2022-01-01 |
| CA3142477A1 (en) | 2020-12-10 |
| EP3980021A4 (en) | 2023-06-14 |
| JP2025032128A (ja) | 2025-03-11 |
| WO2020247706A1 (en) | 2020-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2024201828B2 (en) | Methods of treating and/or preventing actinic keratosis | |
| JP2020090508A (ja) | Ｄｇｌａを含む薬学的組成物及びその使用 | |
| JP6185575B2 (ja) | 皮膚炎症性疾患の治療方法 | |
| TW202112379A (zh) | 治療及／或預防乾癬之方法 | |
| JP2022505215A (ja) | 炎症性、線維性、および増殖性状態を治療するためのｄｇｌａおよび／または１５－ｈｅｔｒｅ | |
| US20150119434A1 (en) | Method for Topically Treating Actinic Keratosis with ingenol 3-(3,5-diethylisoxazole-4-carboxylate) | |
| EP0228239B1 (en) | Preparation of a medicament for arthritis and rheumatism | |
| US20240024273A1 (en) | Topical administration of 2-(diethylamino)ethyl 2-(4-isobutylphenyl)proprionate for treatment of diseases | |
| Wajid | A Comparative Study of the Efficacy and Safety of Topical Calcitriol with Calcitriol and Clobetasol in Chronic Plaque Psoriasis | |
| Barde | Psoriasis and lichen planus | |
| Walton et al. | Nikolaos Tyrogalas, and Javed Mohungoo | |
| CN119454674A (zh) | 伏立诺他在制备治疗银屑病的皮肤外用剂中的应用 | |
| CN120000644A (zh) | 中重度斑块型银屑病的治疗 | |
| CN115487204A (zh) | Α-5,6-二甲基-苯并咪唑氰钴胺在制备治疗21-三体综合征药物中的新用途 | |
| HRP20020201A2 (en) | Pharmaceutical compositions for treating psoriasis | |
| Tate | Chronic psoriasis | |
| HK40020549B (en) | Kx2‑391/kx‑01 for use in the treatment of actinic keratosis | |
| HK40020549A (en) | Kx2‑391/kx‑01 for use in the treatment of actinic keratosis |